Skip to main content
. Author manuscript; available in PMC: 2015 Jun 1.
Published in final edited form as: Mol Cancer Res. 2014 Mar 11;12(6):912–923. doi: 10.1158/1541-7786.MCR-13-0620-T

Figure 5. CDKN2AB status in human mutant KRAS lung adenocarcinoma.

Figure 5

(A) Histogram of p15INK4B mRNA in NSCLC cell lines normalized to GAPDH. (B) Histogram shows the frequency of KRAS mutations and CDKN2A or CDKN2AB inactivation in lung adenocarcinoma in the TCGA data set. (C) Overall survival and (D) progression-free survival curves of patients with lung adenocarcinoma carrying mutant KRAS and/or inactivation of CDKN2A.